AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8410645 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional tactile stimulation (moderate shaking applied to the infant's leg)
Number of subjects: 14
Study 3102387 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 800 mg dose of ofloxacin (32 patients)
Number of subjects: 121
Study 3102387 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 400 mg dose of ofloxacin (55 patients)
Number of subjects: 121
Study 3102387 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice a day dose of 600 mg ofloxacin (34 patients)
Number of subjects: 121
Study 3102387 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin twice a day for 7-10 days (19 patients with urinary tract infection)
Number of subjects: 121
Study 3102387 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin twice a day for 7-10 days (8 patients with enteric fever)
Number of subjects: 121
Study 30602397 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions on the conceptualization of depression
Number of subjects: 81
Study 28040692 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF V600E mutations in MSS patients
Number of subjects: 4411
Study 28040692 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS codon 12 alterations and p.G13D mutations in MSS patients
Number of subjects: 4411
Study 28040692 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF mutations in MSS patients
Number of subjects: 4411
Study 28040692 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutations in MSS patients
Number of subjects: 4411
Study 28040692 — intervention group
Group type: COMPARATOR
Intervention: No mutations in MSI patients
Number of subjects: 4411
Study 25874951 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 300 mg three times daily for 8 weeks
Number of subjects: 38
Study 25874951 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 38
Study 23987126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention discussing evidence about choice disability with local HIV prevention services
Number of subjects: 77
Study 23987126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention discussing an eight-episode audio-docudrama with community groups
Number of subjects: 77
Study 23987126 — intervention group
Group type: EXPERIMENTAL
Intervention: Support groups for women aged 18 to 25 years to build self-esteem and life skills
Number of subjects: 77
Study 23987126 — intervention group
Group type: COMPARATOR
Intervention: Existing prevention efforts (control group)
Number of subjects: 77
Study 21407110 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ng/mL Escherichia coli lipopolysaccharide (LPS)
Number of subjects: 35
Study 21407110 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ng/mL Escherichia coli lipopolysaccharide (LPS)
Number of subjects: 35
Study 21407110 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 35
Study 21407110 — intervention group
Group type: COMPARATOR
Intervention: Control (HCs)
Number of subjects: 35
Study 19216298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical skin protectant lotion (IB1)
Number of subjects: 34
Study 19216298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16753013 — intervention group
Group type: EXPERIMENTAL
Intervention: School curriculum-based exercise program (40 minutes per school day, 200 minutes/week)
Number of subjects: 99
Study 15198188 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 7 days (288 patients)
Number of subjects: 1143
Study 11728541 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 24089
Study 11728541 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rizatriptan
Number of subjects: 24089
Study 11728541 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg eletriptan
Number of subjects: 24089
Study 11728541 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg almotriptan
Number of subjects: 24089
Study 11728541 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg naratriptan
Number of subjects: 24089
Study 11728541 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg eletriptan
Number of subjects: 24089
Study 11728541 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg and 5 mg zolmitriptan
Number of subjects: 24089
Study 11728541 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg eletriptan
Number of subjects: 24089
Study 11728541 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg rizatriptan
Number of subjects: 24089
Study 11728541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24089
Study 9296454 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (n‐acetylcysteine 150 mg/kg for 30 min then 20 mg/kg/h plus bolus doses of 1 g ascorbic acid and 400 mg alpha‐tocopherol)
Number of subjects: 30
Study 9296454 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 30
Study 9296454 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (control)
Number of subjects: 30
Study 8420296 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 290
Study 8420296 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 290
Study 8420296 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin + Gemfibrozil)
Number of subjects: 290
Study 8420296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 3749299 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (20 to 160 mg)
Number of subjects: 0
Study 3749299 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (160 mg)
Number of subjects: 0
Study 3749299 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (various doses including 0, 20, 40, 80, 160 mg)
Number of subjects: 0
Study 3749299 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg)
Number of subjects: 0
Study 31426272 — intervention group
Group type: EXPERIMENTAL
Intervention: SEDDS-CBD (25 mg)
Number of subjects: 16
Study 31426272 — intervention group
Group type: COMPARATOR
Intervention: MCT-CBD
Number of subjects: 16
Study 28135883 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic hyaluronic acid filler
Number of subjects: 10
Study 28135883 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic hyaluronic acid filler
Number of subjects: 10
Study 28135883 — intervention group
Group type: COMPARATOR
Intervention: MRI assessment
Number of subjects: 10
Study 26735229 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary Isocapnic Hyperventilatory Training (VIHT)
Number of subjects: 0
Study 26735229 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study 26735229 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PVIHT)
Number of subjects: 0
Study 25439055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive early interventions (PEI) including skill training for parents of younger children and courses in emotional well-being skills based on cognitive behavioural therapy for older children and youth.
Number of subjects: 0
Study 25439055 — intervention group
Group type: COMPARATOR
Intervention: Pre-emptive early interventions (PEI)
Number of subjects: 0
Study 23311248 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol and midazolam
Number of subjects: 60
Study 23311248 — intervention group
Group type: COMPARATOR
Intervention: General balanced anesthesia (GBA) with midazolam, thiopenton, nitrous oxide, and O2
Number of subjects: 60
Study 19220845 — intervention group
Group type: EXPERIMENTAL
Intervention: Straumann implants
Number of subjects: 28
Study 19220845 — intervention group
Group type: COMPARATOR
Intervention: Brånemark implants
Number of subjects: 28
Study 18569900 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief office intervention (BOI) consisting of four weekly individual sessions lasting 10 to 40 minutes each, incorporating motivational interviewing and cognitive-behavioral techniques.
Number of subjects: 69
Study 18569900 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief office intervention (BOI)
Number of subjects: 69
Study 15748685 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behaviour (TPB) questionnaire
Number of subjects: 120
Study 15748685 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB questionnaire + implementation intention
Number of subjects: 120
Study 15748685 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 12480588 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) in combination with radiotherapy
Number of subjects: 92
Study 12480588 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 92
Study 9792192 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BMI (LBMI) group
Number of subjects: 0
Study 9792192 — intervention group
Group type: COMPARATOR
Intervention: Normal BMI (NBMI) group
Number of subjects: 0
Study 7614107 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid lactulose
Number of subjects: 72
Study 7614107 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystallized lactulose
Number of subjects: 72
Study 7614107 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystallized lactitol
Number of subjects: 72
Study 7614107 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 2533154 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation (surgical oophorectomy or irradiation)
Number of subjects: 0
Study 2533154 — intervention group
Group type: COMPARATOR
Intervention: Depot Zoladex
Number of subjects: 0
Study 920252 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography
Number of subjects: 51
Study 920252 — intervention group
Group type: COMPARATOR
Intervention: Phlebography
Number of subjects: 51
Study 920252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin-fibrinogen degradation products (FDP) assay
Number of subjects: 51
Study 31713129 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic pomegranate juice (SPJ)
Number of subjects: 0
Study 31713129 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic beverage (SB)
Number of subjects: 0
Study 31713129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ)
Number of subjects: 0
Study 31713129 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (PB)
Number of subjects: 0
Study 30985702 — intervention group
Group type: EXPERIMENTAL
Intervention: Short version of the Inventory of Quality for Early Intervention Centers (IQEIC)
Number of subjects: 887
Study 28696503 — intervention group
Group type: EXPERIMENTAL
Intervention: P. pratense allergoid (1800 TU, 6000 TU, 18000 TU)
Number of subjects: 102
Study 28696503 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-grass pollen allergoid (6000 TU)
Number of subjects: 102
Study 28696503 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose P. pratense allergoid (6000 TU)
Number of subjects: 102
Study 28696503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 28696503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose P. pratense allergoid (18000 TU)
Number of subjects: 102
Study 25681064 — intervention group
Group type: EXPERIMENTAL
Intervention: SSM‐VIMT (malaria transmission blocking vaccine)
Number of subjects: 0
Study 25681064 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23555876 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vocalization with pitch-shifted voice (100 cents)
Number of subjects: 0
Study 23555876 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vocalization with pure tones
Number of subjects: 0
Study 23555876 — intervention group
Group type: EXPERIMENTAL
Intervention: Active vocalization with white noise
Number of subjects: 0
Study 23555876 — intervention group
Group type: COMPARATOR
Intervention: Passive listening
Number of subjects: 0
Study 21873356 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 124
Study 21873356 — intervention group
Group type: COMPARATOR
Intervention: Absorbable hemostat
Number of subjects: 124
Study 19752838 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine ER
Number of subjects: 337
Study 19752838 — intervention group
Group type: EXPERIMENTAL
Intervention: fluoxetine
Number of subjects: 337
Study 19752838 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 337
Study 16423942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mL/kg of iohexol over 35 sec (Group A)
Number of subjects: 20
Study 16423942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 mL/kg of iohexol over 35 sec (Group B)
Number of subjects: 20
Study 16423942 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mL/kg of iohexol over 35 sec (Group C)
Number of subjects: 20
Study 16423942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 mL/kg of iohexol over 25 sec (Group D)
Number of subjects: 20
Study 15579515 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1513
Study 11434896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0
Study 11434896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11434896 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline
Number of subjects: 0
Study 9737753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid formulation with 157 Na (270 mOsm x kg(-1))
Number of subjects: 9
Study 9737753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid formulation with Performance (19.6 mEq x L(-1) Na, 380 mOsm)
Number of subjects: 9
Study 9737753 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 9
Study 9737753 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid formulations with 19.6 Na or 19.6 Na + glucose
Number of subjects: 9
Study 9737753 — intervention group
Group type: COMPARATOR
Intervention: Water during exercise
Number of subjects: 9
Study 8070505 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg controlled-release (CR) tablet bd
Number of subjects: 12
Study 8070505 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg controlled-release (CR) tablet bd
Number of subjects: 12
Study 8070505 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 60 mg immediate-release (IR) tablet tid
Number of subjects: 12
Study 2660558 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 200 mg three times a day and 400 mg at night
Number of subjects: 140
Study 2660558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g four times a day orally for four weeks
Number of subjects: 140
Study 2660558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 140
Study 2660558 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 140
Study 30787094 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal Humidified Rapid Insufflation Ventilatory Exchange (THRIVE) with weight appropriate transnasal flow rates and 100% oxygen
Number of subjects: 960
Study 30787094 — intervention group
Group type: COMPARATOR
Intervention: Control (no transnasal oxygen insufflation)
Number of subjects: 960
Study 29888547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 321
Study 29888547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 26965717 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 32
Study 25119686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-bronchodilator microspirometry test (FEV1/FEV6 <0.73)
Number of subjects: 104
Study 22361399 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg intravenously)
Number of subjects: 16
Study 19927040 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC-CRM booster
Number of subjects: 389
Study 19927040 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC-TT booster
Number of subjects: 389
Study 19927040 — intervention group
Group type: EXPERIMENTAL
Intervention: MenC vaccine booster
Number of subjects: 389
Study 19927040 — intervention group
Group type: COMPARATOR
Intervention: MenC-CRM primed
Number of subjects: 389
Study 19927040 — intervention group
Group type: COMPARATOR
Intervention: MenC-TT primed
Number of subjects: 389
Study 17650521 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib, Febuxostat, Pegylated-uricase
Number of subjects: 0
Study 17650521 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 15616045 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution (IH) performed with 500 mL; identical volume of hydroxyethyl starch administered.
Number of subjects: 47
Study 15616045 — intervention group
Group type: COMPARATOR
Intervention: Control group (group CTRL) underwent the same sequences of one-lung ventilation (OLV) without IH.
Number of subjects: 47
Study 15616045 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal lung function (group NL) underwent IH.
Number of subjects: 47
Study 11788629 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose GH (0.025 mg/kg per day)
Number of subjects: 111
Study 11788629 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose GH (0.05 mg/kg per day)
Number of subjects: 111
Study 11788629 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose GH (0.1 mg/kg per day)
Number of subjects: 111
Study 11788629 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study 10430551 — intervention group
Group type: EXPERIMENTAL
Intervention: ET (fentanyl) with 200 microA direct current applied for 30 min at hourly intervals
Number of subjects: 9
Study 10430551 — intervention group
Group type: EXPERIMENTAL
Intervention: ET (fentanyl) with 200 microA direct current applied for 30 min at 4-hourly intervals
Number of subjects: 9
Study 10430551 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl 75 microg infused over 30 min every 4 h
Number of subjects: 9
Study 7560622 — intervention group
Group type: EXPERIMENTAL
Intervention: 12,500 IU of unfractionated heparin given subcutaneously twice daily for 4 months
Number of subjects: 339
Study 7560622 — intervention group
Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 339
Study 2245983 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg clotrimazole vaginal tablet (n = 33)
Number of subjects: 62
Study 7430504 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg prednisone (single dose)
Number of subjects: 15
Study 7430504 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 50 mg prednisone doses given at 6-hr intervals
Number of subjects: 15
Study 6391933 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg fenclofenac per day
Number of subjects: 35
Study 6391933 — intervention group
Group type: COMPARATOR
Intervention: Gold in standard doses
Number of subjects: 35
Study 30912735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (100 g, 72% cocoa)
Number of subjects: 16
Study 28304188 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral left thalamic Vim stimulation (DBS on)
Number of subjects: 1
Study 28304188 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-voltage Vim stimulation
Number of subjects: 1
Study 28304188 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget Vim + Voa stimulation
Number of subjects: 1
Study 28304188 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (DBS off)
Number of subjects: 1
Study 28304188 — intervention group
Group type: COMPARATOR
Intervention: Low-voltage Voa stimulation
Number of subjects: 1
Study 27068478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered iron saccharate (200 mg, two applications)
Number of subjects: 56
Study 27068478 — intervention group
Group type: COMPARATOR
Intervention: Orally administered iron polymaltose complex (100 mg, twice a day for 8 weeks)
Number of subjects: 56
Study 27068478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously administered iron saccharate
Number of subjects: 56
Study 27068478 — intervention group
Group type: COMPARATOR
Intervention: Orally administered iron polymaltose complex
Number of subjects: 56
Study 24846620 — intervention group
Group type: EXPERIMENTAL
Intervention: TelePain intervention (report of symptoms and receipt of a pain graph) weekly for 8 weeks
Number of subjects: 0
Study 24846620 — intervention group
Group type: EXPERIMENTAL
Intervention: TelePain sessions for health care providers (didactic presentation on pain management and patient case discussions)
Number of subjects: 0
Study 22420597 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSRT (Interpersonal and Social Rhythm Therapy)
Number of subjects: 25
Study 22420597 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine (25-300 mg, flexibly dosed)
Number of subjects: 25
Study 19465506 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial hemineglect
Number of subjects: 53
Study 19465506 — intervention group
Group type: COMPARATOR
Intervention: Control for severity of paresis
Number of subjects: 53
Study 18408401 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for breast cancer (clinical breast examination)
Number of subjects: 0
Study 18408401 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for cervix cancer (visual inspection of the cervix after application of 4% acetic acid)
Number of subjects: 0
Study 15939920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 70 mg/qm(2) on day 1 and methotrexate 40 mg/qm(2) on days 8 and 15 of a 21-day cycle (CM)
Number of subjects: 327
Study 15939920 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 30 mg/qm(2) on days 1, 15, and 22, vinblastine 3 mg/qm(2) on days 2, 15, and 22, epirubicin 45 mg/qm(2) on day 2, and cisplatin 70 mg/qm(2) on day 2 of a 28-day cycle (M-VEC)
Number of subjects: 327
Study 12424822 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics (AN)
Number of subjects: 75
Study 12424822 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical neuroleptics (CN)
Number of subjects: 75
Study 12424822 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 75
Study 12424822 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of neuroleptic treatment
Number of subjects: 75
Study 12424822 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of illness
Number of subjects: 75